Avantium (AVTX) investor relations material

Executive summary

• Advanced commissioning of the FDCA Flagship Plant, with the oxidation unit operational and purification unit nearing completion; first commercial FDCA production targeted for end of 2026.

• Secured 22 offtake agreements and 15 capacity reservations for FDCA and PEF, with strong licensing momentum and regulatory support in Europe and globally.

• Strategic focus sharpened through divestment of Ray Technology®, spin-out of Volta and Parana Technologies, and discontinuation of Dawn Technology® investments.

• Organization strengthened with new COO and CFO appointments, and a 15% reduction in headcount as part of cost control and right-sizing.

Financial highlights

• H1 2026 revenue was €4.7 million, down from €6.7 million in H1 2025, mainly due to lower R&D Solutions sales.

• EBITDA loss was €18.8 million (H1 2025: €18.5 million); net operating expenses were €27.0 million.

• Cash position at 30 June 2026 was €23.9 million, down from €57.5 million at year-end 2025.

• €2.7 million gain from sale of Ray Technology® IP; net cash outflow of €33.6 million in H1 2026.

• Additional €7 million capex due to titanium welding remediation at the FDCA plant, causing delays and shifting revenue timing.

Outlook and guidance

• Focus for H2 2026 is on producing first FDCA batches, completing qualification, and starting commercial sales by year-end.

• Plant ramp-up to full capacity expected by H2 2028; ongoing expansion of offtake agreements and licensing discussions.

• Anticipated product sales income from FDCA and PEF, with milestone payments from new licensees.